GCP
TEVA icon

GSA Capital Partners’s Teva Pharmaceuticals TEVA Stock Holding History

GSA Capital Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-12,876
Closed -$216K – 2082
2025
Q2 		$216K Buy
12,876
+2,496
+24% +$40.3K 0.02% 1471
2025
Q1 		$160K Buy
+10,380
New +$185K 0.01% 1447
2022
Q1 		– Sell
-15,883
Closed -$127K – 1823
2021
Q4 		$127K Buy
+15,883
New +$143K 0.02% 1294
2020
Q3 		– Sell
-13,200
Closed -$163K – 1385
2020
Q2 		$163K Buy
+13,200
New +$149K 0.09% 399
2020
Q1 		– Sell
-15,805
Closed -$155K – 1542
2019
Q4 		$155K Sell
15,805
-5,563
-26% -$49.7K 0.02% 1305
2019
Q3 		$147K Buy
+21,368
New +$164K 0.02% 1230
2016
Q4 		– Sell
-15,322
Closed -$705K – 1957
2016
Q3 		$705K Buy
15,322
+10,913
+248% +$569K 0.04% 842
2016
Q2 		$221K Sell
4,409
-2,611
-37% -$139K 0.01% 1523
2016
Q1 		$376K Buy
+7,020
New +$412K 0.02% 1178
2015
Q3 		– Sell
-8,055
Closed -$476K – 2010
2015
Q2 		$476K Buy
+8,055
New +$497K 0.02% 1380
2014
Q3 		– Sell
-4,352
Closed -$228K – 1928
2014
Q2 		$228K Buy
+4,352
New +$222K 0.01% 1552

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

GSA Capital Partners's TEVA Position: Q3 2025 in Review

GSA Capital Partners sold out of Teva Pharmaceuticals (TEVA) in Q3 2025, closing a stake of 12,876 shares — an estimated $216K sold.

GSA Capital Partners first reported a position in TEVA in Q2 2014 and held it in 11 quarters. The position peaked at $705K in Q3 2016. 550 funds tracked by Wall St. Rank hold TEVA as of Q3 2025.

  • GSA Capital Partners reported no remaining Teva Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • GSA Capital Partners sold 12,876 Teva Pharmaceuticals shares in Q3 2025, an estimated $216K.
  • GSA Capital Partners first reported a position in Teva Pharmaceuticals in Q2 2014 and held it in 11 quarters.
  • GSA Capital Partners's Teva Pharmaceuticals position peaked at $705K in Q3 2016.
  • 550 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2025.

Based on GSA Capital Partners's 13F filing for Q3 2025, filed 7 Nov 2025.